Motus GI Holdings PE Ratio 2016-2024 | MOTS
Current and historical p/e ratio for Motus GI Holdings (MOTS) from 2016 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Motus GI Holdings PE ratio as of June 11, 2026 is 0.00.
| Motus GI Holdings PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2026-06-10 | 0.00 | 0.00 | |
| 2024-03-31 | 0.44 | $-2.96 | 0.00 |
| 2023-12-31 | 1.28 | $-15.89 | 0.00 |
| 2023-09-30 | 6.75 | $-27.47 | 0.00 |
| 2023-06-30 | 10.05 | $-50.18 | 0.00 |
| 2023-03-31 | 14.60 | $-72.07 | 0.00 |
| 2022-12-31 | 12.60 | $-86.15 | 0.00 |
| 2022-09-30 | 36.75 | $-109.00 | 0.00 |
| 2022-06-30 | 84.48 | $-111.99 | 0.00 |
| 2022-03-31 | 107.97 | $-113.94 | 0.00 |
| 2021-12-31 | 140.10 | $-161.02 | 0.00 |
| 2021-09-30 | 206.85 | $-161.77 | 0.00 |
| 2021-06-30 | 312.00 | $-170.76 | 0.00 |
| 2021-03-31 | 363.00 | $-185.91 | 0.00 |
| 2020-12-31 | 284.40 | $-179.91 | 0.00 |
| 2020-09-30 | 293.22 | $-209.90 | 0.00 |
| 2020-06-30 | 396.00 | $-224.89 | 0.00 |
| 2020-03-31 | 202.14 | $-257.87 | 0.00 |
| 2019-12-31 | 687.00 | $-275.86 | 0.00 |
| 2019-09-30 | 594.00 | $-308.85 | 0.00 |
| 2019-06-30 | 909.00 | $-353.82 | 0.00 |
| 2019-03-31 | 1170.00 | $-356.82 | 0.00 |
| 2018-12-31 | 933.00 | $-440.78 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.000B | $0.000B |
| Motus GI Holdings, Inc. is a medical technology company. It focuses on the development and commercialization of the Pure-Vu(R) System to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. The company also operates through subsidiaries in the U.S. and Israel. Motus GI Holdings, Inc. is based in FL, United States. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $24.733B | 27.19 |
| Tempus AI (TEM) | United States | $7.677B | 0.00 |
| Hims & Hers Health (HIMS) | United States | $4.429B | 38.86 |
| Doximity (DOCS) | United States | $3.888B | 16.84 |
| IRhythm Holdings (IRTC) | United States | $3.724B | 0.00 |
| 10x Genomics (TXG) | United States | $2.973B | 0.00 |
| Privia Health (PRVA) | United States | $2.810B | 131.59 |
| Hinge Health (HNGE) | United States | $2.789B | 0.00 |
| Heartflow (HTFL) | United States | $2.311B | 0.00 |
| Omnicell (OMCL) | United States | $1.564B | 43.00 |
| Inspire Medical Systems (INSP) | United States | $1.555B | 20.94 |
| Enovis (ENOV) | United States | $1.405B | 7.40 |
| Butterfly Network (BFLY) | United States | $1.047B | 0.00 |
| Azenta (AZTA) | United States | $1.023B | 41.13 |
| Clover Health Investments (CLOV) | United States | $1.013B | 0.00 |
| Talkspace (TALK) | United States | $0.864B | 103.40 |
| Schrodinger (SDGR) | United States | $0.839B | 0.00 |
| Phreesia (PHR) | United States | $0.490B | 50.38 |
| Fulgent Genetics (FLGT) | United States | $0.429B | 0.00 |
| Standard BioTools (LAB) | United States | $0.345B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.322B | 0.00 |
| CapsoVision (CV) | United States | $0.311B | 0.00 |
| Senseonics Holdings (SENS) | United States | $0.279B | 0.00 |
| Claritev (CTEV) | United States | $0.269B | 0.00 |
| TruBridge (TBRG) | United States | $0.268B | 8.60 |
| Evolent Health (EVH) | United States | $0.260B | 0.00 |
| Carlsmed (CARL) | United States | $0.239B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.196B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.189B | 0.00 |
| CareCloud (CCLD) | United States | $0.115B | 8.18 |
| Nyxoah SA (NYXH) | Belgium | $0.111B | 0.00 |
| Insight Molecular Diagnostics (IMDX) | United States | $0.102B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.101B | 0.00 |
| American Well (AMWL) | United States | $0.086B | 0.00 |
| Outset Medical (OM) | United States | $0.077B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.073B | 0.00 |
| Pulmonx (LUNG) | United States | $0.058B | 0.00 |
| 111 (YI) | China | $0.057B | 0.00 |
| NetraMark Holdings (AINMF) | Canada | $0.052B | 0.00 |
| Precipio (PRPO) | United States | $0.049B | 0.00 |
| HeartBeam (BEAT) | United States | $0.047B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.034B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.020B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.018B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.017B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.011B | 0.00 |
| Lunai Bioworks (LNAI) | United States | $0.009B | 0.00 |
| Zhongchao (ZCMD) | China | $0.008B | 0.00 |
| HeartSciences (HSCS) | United States | $0.007B | 0.00 |
| ITonic Holdings (ITOC) | China | $0.005B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.003B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.002B | 0.00 |
| PROFUSA (PFSA) | United States | $0.001B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.001B | 0.00 |